FDA Approves the First Eye-Specific Bevacizumab, Ending Two Decades of Pharmacy Repackaging for Wet AMD
FDA-approved Lytenava, the first ophthalmic bevacizumab for wet AMD, replaces compounded repackaging of a cancer drug. What changes for patients.
Medical Daily ·